Anaveon To Take A Different Clinical Path With Novel IL-2 Therapy

Interleukin-2 Agonist Being Assessed In Solid tumors

 
• By Sten Stovall

Anaveon of Switzerland plans to take the clinical road less travelled with its novel interleukin-2 agonist, ANV419, its CEO told Scrip as the firm launched a Phase I/II study for its lead asset.

Cancer cells on scientific background.3d illustration
Anaveon CEO Tells Scrip Compound Can Improve On Limitations Posed By Interleukin-2 • Source: Shutterstock

More from Clinical Trials

More from R&D